BI
VTGN icon

BVF Inc’s VistaGen Therapeutics VTGN Stock Holding History

BVF Inc’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,000,000
Closed -$6.02M – 58
2024
Q3 		$6.02M Hold
2,000,000
– – 0.18% 41
2024
Q2 		$6.96M Hold
2,000,000
– – 0.2% 41
2024
Q1 		$10.6M Hold
2,000,000
– – 0.29% 40
2023
Q4 		$10.3M Buy
+2,000,000
New +$7.57M 0.26% 47

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BVF Inc's VTGN Position: Q4 2024 in Review

BVF Inc sold out of VistaGen Therapeutics (VTGN) in Q4 2024, closing a stake of 2,000,000 shares — an estimated $6.02M sold.

BVF Inc first reported a position in VTGN in Q4 2023 and held it in 4 quarters. The position peaked at $10.6M in Q1 2024. 54 funds tracked by Wall St. Rank hold VTGN as of Q4 2024.

  • BVF Inc reported no remaining VistaGen Therapeutics position as of Q4 2024 after selling out during the quarter.
  • BVF Inc sold 2,000,000 VistaGen Therapeutics shares in Q4 2024, an estimated $6.02M.
  • BVF Inc first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 4 quarters.
  • BVF Inc's VistaGen Therapeutics position peaked at $10.6M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2024.

Based on BVF Inc's 13F filing for Q4 2024, filed 14 Feb 2025.